REVERSE PHASE LIQUID CHROMATOGRAPHIC METHOD FOR ANALYSIS OF DOXOFYLLINE IN PRESENCE OF ITS DEGRADATION PRODUCTS
Nirmal Chaudhary, M Alam
Karnali College of Health Sciences (Purbanchal University), Kathmandu-44600, Nepal
Keywords: Doxofylline, Forced degradation studies, Method development, Validation
Abstract

A simple, precise and novel reverse phase liquid chromatographic method for analysis of doxofylline in bulk drug as well as in pharmaceutical preparations in the presence of potential degradation products of doxofylline has been developed and validated. Forced degradation studies were carried on doxofylline in acidic, neutral and alkaline hydrolytic conditions in addition to oxidative, thermal and photolytic conditions. Optimum separation among doxofylline and its degradation products was achieved using a ternary mixture of water: methanol: ethyl acetate in the ratio of 80:10: 10 % v/v/v as the mobile phase at a flow rate of 1.0 ml/min on a Supelco C18 DB 150 mm X 4.6 mm column as the stationary phase when scanned at a wavelength of 277 nm. The retention time for the various degradation products were found to be sufficiently different with each other as well as with the parent drug at the optimized chromatographic conditions to permit their accurate quantitative estimation. The method was found to be linear at least in the range of 5-25 µg/ml. The developed method was then validated for precision, accuracy, specificity, robustness and ruggedness in accordance with the ICH guidelines and other available regulatory guidelines.

Article Information

Identifiers and Pagination:
Year:2014
Volume:6
First Page:187
Last Page:197
Publisher Id:JAppPharm (2014 ). 6:3. 187-197
Article History:
Received:March 20, 2014
Accepted:March 28, 2014
Collection year:2014
First Published:April 1, 2014

INTRODUCTION

Doxofylline is chemically, 7-(1, 3-Dioxolon-2-yl methyl)-3, 7-dihydro- 1, 3-dimethyl-1H purine- 2, 6-dione   [Figure 1].  Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase [1]. It has a better safety profile, because of reduced affinity for adenosine A1 and A2 receptors. Moreover, unlike theophylline, doxofylline does not antagonize calcium-channel-blocker receptors nor does it interfere with the influx of calcium into cells. Doxofylline is used in the treatment of bronchial asthma, chronic obstructive pulmonary disease (COPD), and chronic bronchitis. It is given orally in doses of up to 1,200 mg daily either as tablets or syrup. It may also be given by slow intravenous injection.

An extensive literature survey revealed analytical methods [2-20] reported for estimation of doxofylline. Most of the methods reported are for estimation of doxofylline alone or along with its metabolites in biological fluids such [2-11]. The reported methods for estimation of doxofylline in pharmaceutical formulations available are [11-20] of which methods [11-15] are for estimation of doxofylline in single component formulations whereas methods [16-20] are reported for estimation of doxofylline in multi-component formulations. Most of these methods are based on chromatographic and spectrophotometric methods. However, only few stability indicating analytical methods for estimation of doxofylline [15-17] are reported in literature so far. In this paper we report a novel analytical method which provides a simple, rapid, precise and accurate method for determination of doxofylline in the presence of its potential degradation products.

Figure 1: Structural formula of Doxofylline

EXPERIMENTAL

Instrumentation

Shimadzu HPLC system provided with Shimadzu HPLC pump LC-10AT Vp, on line degasser DGU-14A, low pressure gradient flow control unit FCV-10AL Vp, universal injector 2E 7725 (Rheodyne) with 20 µl loop, Hamilton micro liter syringe 25 µl, column oven CTO-10AS Vp, variable wavelength UV-VIS detector SPD-10AVp with Shimadzu class CSW software, C18 -column (Supelco, 4.6 mm × 150 mm) was used for method development.

Chemicals, Reagents and Solutions

Pure doxofylline was generously gifted by Dr. Reddy’s Laboratory, Hyderabad, India. The marketed preparations of doxofylline used in the study, Doxobid was purchased from the local market. All the chemicals and solvents used were of HPLC grade. Double distilled water and Whatmann filter paper Grade-I, 0.45-mm filter paper were used throughout the experimental work.

Preparation of Standard Solution

An accurately weighed quantity of doxofylline (10 mg) was taken in 100 ml volumetric flask and dissolved in about 20-25 ml of methanol and made up to the volume to obtain a standard stock solution of doxofylline of 1 mg/ml concentration. One milliliter of this standard stock solution was transferred to a 100 ml volumetric flask and the volume was made up to the mark with mobile phase so as to obtain a working standard of 10 mg/ml concentration.

Preparation of Sample Solution

Twenty tablets were weighed and finely powdered. An accurately weighed tablet powder equivalent to 5 mg of doxofylline was transferred into a 50 ml volumetric flask containing little methanol. The flask content was agitated for 30 min on a wrist shaker to release the drug from the tablet matrix. Then, the volume was adjusted to the mark with methanol and sonicated for 15 min to make the content homogeneous. The solution was then filtered through Whatmann Grade I filter paper to obtain a resultant sample solution of 100 mg/ml concentration. Five milliliters of the filtrate was then transferred to 50 ml volumetric flask and the volume was made up to the mark with mobile phase to get a final concentration of 10 mg/ml of doxofylline.

Force Degradation (Stress Studies) of Doxofylline

Stress studies were performed on pure doxofylline and one of its marketed preparations Doxobid by exposing them to various stress conditions over wide range of pH, heat, oxidation and photo degradation separately.

Hydrolytic degradation under acidic, neutral and alkaline condition was carried by transferring 50 mg of Doxofylline in each of the three round bottom flask and dissolving them separately using 50ml of 0.1N aqueous hydrochloric acid, 50 ml of double distilled water and 50 ml of 0.1N aqueous sodium hydroxide respectively followed by refluxing them on a thermostatic water bath at 70°C. 

Oxidative degradation was carried out both at ambient temperature and by refluxing at 70°C. This was carried taking into consideration the facts that – (a) many of the oxidative degradation products formed are thermally unstable and may decompose at higher temperatures, (b) the observed oxidative rates and pathways may be different than those observed at higher temperatures and this may lead to different oxidation degradation product as the O–O bond of hydrogen peroxide is a weak bond that will readily cleave at elevated temperatures to form hydroxyl radicals which is a much harsher oxidative reagent and (c) the reaction rate in solution may actually be reduced at higher temperatures because of the decrease in oxygen content of the solvent. For oxidative degradation, 50 mg each of doxofylline were dissolved in 50 ml of 3 % H2O2 (1 mg/ml) in each of the two round bottom flasks separately. One of the round bottom flasks was refluxed on water bath maintained at 70°C. The other round bottom flask was kept at room temperature (RT).

Photolytic degradation was carried by evenly spreading doxofylline as thin layer in a covered petridish and exposing in sunlight. Thermolytic degradation was carried by transferring doxofylline in covered petridish kept in an oven maintained at a temperature of 80°C.

Similarly, the various degradation products of Doxobid were prepared by exposing equivalent quantity of Doxobid tablet powder and treating in similar manner as in the case of preparation of forced degradation samples of pure doxofylline.

The samples which showed no degradation at the initial stress conditions were subjected to increasingly more severe stress conditions till a maximum limit was reached. The maximum stress conditions to be subjected were determined based on the available regulatory guidelines, the current pharmaceutical stress testing trends and/or practical constraints imposed by the physicochemical properties of the molecule.

Sampling of Force Degradation Products

Five milliliters of all hydrolytic and refluxed oxidative degradation samples (1 mg/ml) were withdrawn during hydrolysis under acidic and alkaline conditions every 1st, 3rd, 5th and 8th hour and stored under refrigeration. For oxidative degradation sample at RT, 5 ml samples were sampled at intervals of 1, 3, 5 & 7 days.  In case of thermal and photo degradation studies, 10 mg samples were withdrawn after 7th, 14th and 30th day and dissolved in 10 ml of methanol to obtain a resultant concentration of 1 mg/ml each.

Preparation of Degradation Sample for HPLC

All the stock degradation samples collected (1 mg/ml each) were diluted with mobile phase so that the final working solutions of all forced degradation products were of the concentration 10 mg/ml with respect to the parent drug.

Chromatographic Conditions

All the experimental work was performed on Shimadzu HPLC system using   C18 -column (Supelco, 4.6 mm × 150 mm). The mobile phase containing mixture of water: methanol: ethyl acetate in the ratio of 80:10: 10 % v/v/v, was found to be most satisfactory as it gave good resolution of drug and degradation products peaks with reasonable symmetry. Figure 2 shows HPLC chromatogram of doxofylline.  The wavelength of 277 nm, the ?max of pure doxofylline itself in the said mobile phase as determined by its UV spectroscopy was found to be sensitive enough to detect both the parent drug and its degradation products. A flow rate of 1 ml/min with 25oC column oven temperature was found to be optimum. The retention times under the optimized chromatographic conditions was found to be 6.28 ± 0.02 min with an asymmetry factor of 1.15 ± 0.03. A total run time of about 9 min of the chromatogram was able to depict the peaks for doxofylline and all of its potential degradation products.  

Figure 2: HPLC chromatogram of Doxofylline

Stability of Standard and Sample Solutions

The chromatograms of the same working standard and sample solution were obtained periodically over a period of 24 hours and the solutions of both the standard drug and sample were found to be stable in the tested duration. The results are shown in following Table 1.

Table 1: Results of stability of standard and sample solutions

System Suitability Test (SST)

SST is commonly used to verify resolution, column efficiency, and repeatability of the chromatographic system to ensure its adequacy for a particular analysis. Results of SST carried are shown in Table 2.

Table 2: Result of system suitability studies

Linearity study

A plot of peak area versus concentration [Figure 3] showed that the method was found to be linear at least in the range of 5-25 µg/ml. The regression equation was found to be y = 13.754x + 2.9881 and the coefficient of regression was 0.9991.

Figure 3: Calibration curve of Doxofylline

RESULTS AND DISCUSSION

HPLC Method Development and Optimization

The chromatographic separation of doxofylline and its degradation products was done on reverse phase C18 column. The mobile phase containing mixture of water: methanol: ethyl acetate in the ratio of 80:10: 10 % v/v/v was found to be most satisfactory as it gave good resolution of drug and degradation products with reasonably symmetrical sharp peaks. The detection wavelength of 277 nm, the ?max of pure doxofylline itself was optimum as the degradation products of doxofylline showed substantial absorbance to be detected at this wavelength. A flow rate of 1 ml/min with 25oC column oven temperature was found to be optimum.  The retention time for the parent drug under the optimised chromatographic conditions was found to be 6.28 ± 0.02 min with an asymmetry of 1.15 ± 0.03. A total run time of 9 min was sufficient to depict all the degradation products of doxofylline [Figure 4(a-h)].  Stress studies on one of the marketed formulation Doxobid, showed similar results to that of the bulk drug with no any additional peaks or interference indicating that the proposed method could be used for estimation of doxofylline in the presence of its potential degradation products in pharmaceutical preparations as well.

Figure 4(a): Chromatogram - Acidic hydrolysis in 0.1 N aq. HCl at 70°C (3 hrs)

Figure 4(b): Chromatogram - Alkaline hydrolysis in 0.1 N aq. NaOH at 70°C (5 hrs)

Figure 4(c): Chromatogram - Neutral hydrolysis in water at 70°C (8 hrs)

Figure 4(d): Chromatogram - Oxidative degradation in 3% H2O2 at RT for 7 days 

Figure 4(e): Chromatogram - Oxidative degradation in 3% H2O2 at 70°C for 7 days              

Figure 4(f): Chromatogram- Thermal degradation at 80°C (30 days)

Figure 4(g): Chromatogram- Photodegradation in sunlight (30 days)

Figure 4(h): Chromatogram - Mixture of Doxofylline Degradation Products

Figure 4(a-h): Results of various forced degradation study

Validation of Proposed Method

As recommended in ICH guidelines [21, 22], all validation studies were performed during development of the procedure. The proposed method was validated for linearity & range, limit of detection & limit of quantitation, precision, accuracy, specificity and ruggedness. The results of precision, accuracy, specificity and ruggedness studies are shown in Tables 3, 4, 5 & 6 respectively.

Table 3: Results of system, method and intermediate precision

Table 4: Results of recovery (accuracy) studies

CONCLUSION

The method is simple, precise and accurate for the determination of doxofylline and its degradation product in bulk drug and pharmaceutical preparations. It was validated for parameters like precision, accuracy, specificity, ruggedness and robustness and was found to yield good results. The method can therefore be applied for routine quality control analysis of doxofylline in pharmaceutical preparations.

 

ACKNOWLEDGEMENTS

 The authors extend their sincere thanks to Dr. Reddy’s Laboratory, Hyderabad, India for providing gift sample of pure doxofylline.

 

 

REFERENCES

1.         Cirillo R, Barone D, Franzone JS. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Arch Int Pharmacodyn Ther. 1988; 295:221–237.

2.         Gannu R, Bandari S, Sudke SG, Rao YM, Shankar BP. Development and Validation of a Stability-Indicating RP-HPLC Method for Analysis of Doxofylline in Human Serum, Application of the Method to a Pharmacokinetic Study. Acta Chromatogr. 2007; 19:149-157.

3.         Sreenivas N, Narasu ML, Shankar BP, Mullangi R. Development and validation of a sensitive LCMS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. Biomed Chromatogr. 2008; 22(6):654-661.

4.         Lagana A, Bizzarri M, Marino A, Mancini M. Solid phase extraction and high performance liquid chromatographic determination of doxofylline in plasma. Biomed Chromatogr. 1990; 4(5):205–207.

5.         Unping G, Hongbo W, Yinjie F. Determination of Doxofylline in Plasma by SPE-HPLC. China Pharmacist, 2005; 4.

6.         Tagliaro F, Dorizzi R, Frigerio A, Marigo M. Non-extraction HPLC method for simultaneous measurement of dyphylline and doxofylline in serum. Clin Chem. 1990; 36(1):113-115.

7.         Yifang L, Weimin S, Jie S, Zhongjuan1S, Yun X. Determination of  Theophylline and Doxofylline in Human Plasma by HPLC. Chin J Pharm. 2010; 2.

8.         Shujun W, Lifeng W, Jianhua X, Kangshou Z. Determination of doxofylline concentration in human serum by HPLC. Chin J Clin Pharm. 2003; 6.

9.         Yanggui X, Yishan B, Zhenmei H, Chunyang W, Jun L, Zhongyang G. Determination of Doxofylline Concentration in Plasma by RP-HPLC. China Pharmacist. 2002; 8.

10.      Yinxiu Y, Wenxing P, Huande L. Bioequivalence of Doxofylline in Healthy Volunteers. J China Pharma University. 1998; 5.

11.      Quan-cheng K, Duo-lu L, Xiu-qin S. HPLC determination of doxofylline and pharmacokinetic study in serum of patients with chronic obstructive pulmonary disease. Chin J Pharm Anal. 2009; 5.

12.      Kamila MM, Mondal N, Ghosh LK. Development and validation of spectrophotometric method for estimation of antiasthmatic drug doxofylline in bulk and pharmaceutical formulation, Indian J Chem Tech. 2007; 14:523-525.

13.      Joshi HR, Patel AH, Captain AD. Spectrophotometric and Reversed-Phase High- Performance Liquid Chromatographic Method for the Determination of Doxofylline in Pharmaceutical Formulation. J Young Pharm. 2010; 1:141-145.

14.      Mittal A, Parmar S. Development and validation of rapid HPLC method for determination of doxofylline in bulk drug and pharmaceutical dosage forms. J Ana Chem. 2010; 65:293-297.

15.      Zi-li X. Determination of doxofylline in doxofylline injection by GC method. Anhui Med Pharm J. 2006; 9.

16.      Patre NG, Sathiyanarayanan L, Mahadik MV, Dhaneshwar SR. A validated, stability indicating HPTLC method for analysis of doxofylline. J Planar Chromatogr- Mod TLC. 2009; 22(5):345-348.

17.      Rao RN, Naidu ChG, Prasad KG, Santhakumar B, Saida S. Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, ¹H and ¹³C NMR spectroscopic characterization of degradation products and process related impurities. J Pharm Biomed Anal. 2013; 78-79:92-99.

18.      Gupta A, Rawat S, Gandhi M, Yadav JS. Method Development and Acid Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS; Asian J Pharm Ana. 2011; 1:29-33.

19.      Chauhan PS, Panchal VU, Patel GF. Development & validation of derivative spectrophotometric method for simultaneous estimation of doxofylline & ambroxol HCl in their bulk dosage form, Universal J. Pharm. 2013; 02(01):154-159.

20.      Jain A, Khandhar AP, Maheshwari S, Maliwal D. Analytical Method Development, Validation and Comparison of Spectrophotometric and Stability Indicating HPLC Methods for the Simultaneous Estimation of Doxofylline and Montelukast in Pharmaceutical Dosage Form. AAPS Annual Meeting and Exposition November 10, 2009.

21.      International Conference on Harmonization  of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures, ICH-Q2A, Geneva (1995).

22.   International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures: Methodology, ICH-Q2B, Geneva (1996). 


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/